Bioengineered protein shows preliminary promise as new therapy for hemophilia

October 23, 2011 in Genetics

A genetically engineered clotting factor that controlled hemophilia in an animal study offers a novel potential treatment for human hemophilia and a broad range of other bleeding problems.

The researchers took the naturally occurring coagulation factor Xa (FXa), a protein active in blood clotting, and engineered it into a novel variant that safely controlled bleeding in mouse models of hemophilia. "Our designed variant alters the shape of FXa to make it safer and efficacious compared to the wild-type factor, but much longer-lasting in ," said study leader Rodney A. Camire, Ph.D., a researcher at The Children's Hospital of Philadelphia.

"The shape of the variant FXa changes when it interacts with another clotting factor made available following an injury," added Camire. "This increases the functioning of the protein which helps stop bleeding." Camire is an associate professor of Pediatrics in the Perelman School of Medicine at the University of Pennsylvania.

The study appears online today in , and will be published in the journal's November 2011 print issue.

In hemophilia, an inherited single-gene mutation impairs a patient's ability to produce a blood-clotting protein, leading to spontaneous, sometimes life-threatening bleeding episodes. The two major forms of the disease, which occurs almost solely in males, are hemophilia A and hemophilia B, characterized by which specific clotting factor is deficient. Patients are treated with frequent infusions of clotting proteins, which are expensive and sometimes stimulate the body to produce antibodies that negate the benefits of treatment.

Roughly 20 to 30 percent of patients with hemophilia A and 5 percent of hemophilia B patients develop these inhibiting antibodies. For those patients, the conventional treatment, called "bypass therapy," is to use drugs such as factor VIIA and activated prothrombin complex concentrates (aPCCs) to restore blood clotting capability. But these agents are costly (as much as $30,000 per treatment) and not always effective. Camire added that, in the current , they were able to show the variant protein is more effective at a lower dose than FVIIa.

The range of options for hemophilia patients could improve if the study results in animals were to be duplicated in humans. "The variant we have developed puts FXa back on the table as a possible therapeutic agent," said Camire. Naturally occurring (wild-type) FXa, due to its particular shape, is not useful as a therapy because normal biological processes shut down its functioning very quickly.

By custom-designing a different shape for the FXa protein, Camire's study team gives it a longer period of activity, while limiting its ability to engage in unwanted biochemical reactions, such as triggering excessive clotting. "This potentially could lead to a new class of bypass therapy for hemophilia, but acting further downstream in the clot-forming pathway than existing treatments," said Camire, who has investigated the biochemistry of blood-clotting proteins for more than a decade.

When infused into mice with hemophilia, the FXa variant reduced blood loss after injury, as it safely restored ability. Further studies are necessary in large animal models to determine whether this approach can become a clinical treatment for patients who have developed inhibitors, or even more broadly as a drug for uncontrolled bleeding in other clinical situations.

More information: "A zymogen-like factor Xa variant corrects the coagulation defect in hemophilia," Nature Biotechnology, published online Oct. 23, 2011, to appear in Nov. 2011 print edition. doi: 10.1038/nbt.1995

Provided by Children's Hospital of Philadelphia search and more info website

not rated yet  

Rank not rated yet
Relevant PhysicsForums posts

More news stories

Researchers complete largest genetic sequencing study of human disease

Researchers from Queen Mary, University of London have led the largest sequencing study of human disease to date, investigating the genetic basis of six autoimmune diseases.

Genetics created 1 hour ago | popularity not rated yet | comments 0 | with audio podcast

Researchers develop model for better testing, targeting of malignant peripheral nerve sheath tumors

University of Minnesota Medical School researchers from the Masonic Cancer Center, University of Minnesota, in partnership with the University's Brain Tumor Program, have developed a new mouse model of malignant peripheral ...

Genetics created May 20, 2013 | popularity 5 / 5 (1) | comments 0 | with audio podcast

Researchers identify new circadian clock component

Northwestern University scientists have shown a gene involved in neurodegenerative disease also plays a critical role in the proper function of the circadian clock.

Genetics created May 16, 2013 | popularity 3 / 5 (1) | comments 1 | with audio podcast

Returning genetic incidental findings without patient consent violates basic rights, experts say

Informed consent is the backbone of patient care. Genetic testing has long required patient consent and patients have had a "right not to know" the results. However, as 21st century medicine now begins to use the tools of ...

Genetics created May 16, 2013 | popularity 5 / 5 (1) | comments 3 | with audio podcast

Ethicists provide framework supporting new recommendations on reporting incidental findings in gene sequencing

In a paper published in Science Express, a group of experts led by bioethicists in the Center for Medical Ethics and Health Policy at Baylor College of Medicine provide a framework for the new American College of Medical Geneti ...

Genetics created May 16, 2013 | popularity not rated yet | comments 0


Enzyme-activating antibodies revealed as marker for most severe form of rheumatoid arthritis

In a series of lab experiments designed to unravel the workings of a key enzyme widely considered a possible trigger of rheumatoid arthritis, researchers at Johns Hopkins have found that in the most severe ...

Research offers promising new approach to treatment of lung cancer

Researchers have developed a new drug delivery system that allows inhalation of chemotherapeutic drugs to help treat lung cancer, and in laboratory and animal tests it appears to reduce the systemic damage ...

Researchers analyse hunting behaviour of fish larvae in virtual reality

Moving objects attract greater attention – a fact exploited by video screens in public spaces and animated advertising banners on the Internet. For most animal species, moving objects also play a major ...

Overeating learned in infancy, study suggests

In the long run, encouraging a baby to finish the last ounce in their bottle might be doing more harm than good.

Study details genes that control whether tumors adapt or die when faced with p53 activating drugs

When turned on, the gene p53 turns off cancer. However, when existing drugs boost p53, only a few tumors die – the rest resist the challenge. A study published in the journal Cell Reports shows how: tumors that live even i ...

Children of married parents less likely to be obese

Children living in households where the parents are married are less likely to be obese, according to new research from Rice University and the University of Houston.